Psyence BioMed unit signs term sheet with PsyLabs for exclusive U.S. ibogaine license, supply deal
Bitget2026/09/28 11:01- Psyence Biomedical entered a binding term sheet with PsyLabs for exclusive U.S. rights to pharmaceutical-grade ibogaine via its Texas unit.
- Texas Ibogaine Research Corporation would receive exclusive development, supply, wholesale distribution rights, subject to a definitive agreement by Nov. 30, 2026.
- PsyLabs would remain the exclusive supplier; the license includes manufacturing know-how, specifications, technical documentation for ibogaine hydrochloride.
- Consideration includes up to about USD 1.3 million in development and regulatory milestones for the first drug candidate.
- Additional economics include a low single-digit royalty on net sales, an annual exclusivity fee after first FDA approval, and margin-sharing on resale.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
The British Pound rallies on a UK growth upgrade and gives more than half back
Only twice in history! S&P 500 equal-weight index is expected to record seven consecutive weeks of decline this week
The S&P 500 Equal Weight Index is expected to fall for a seventh consecutive week. If this downward trend continues through Friday, it will mark only the third time in history that the index has experienced seven straight weeks of decline.
Trump “bites” Powell, demanding his resignation from the Federal Reserve Board, citing severe cost overruns in headquarters renovation.
U.S. President Trump on Wednesday called for former Federal Reserve Chairman Powell to resign from his position as a Fed governor, following an inspector general report on the Federal Reserve headquarters renovation project, which highlighted a series of management issues that led to significant cost overruns.
Crypto prices
More
